PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients

Detalles Bibliográficos
Autores principales: Lu, P, Hsu, J, Keane, C, Fettner, S, Wang, J, Ruperto, N, Harari, O, Brunner, HI, De Benedetti, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042527/
http://dx.doi.org/10.1186/1546-0096-11-S2-P171
_version_ 1782318825466757120
author Lu, P
Hsu, J
Keane, C
Fettner, S
Wang, J
Ruperto, N
Harari, O
Brunner, HI
De Benedetti, F
author_facet Lu, P
Hsu, J
Keane, C
Fettner, S
Wang, J
Ruperto, N
Harari, O
Brunner, HI
De Benedetti, F
author_sort Lu, P
collection PubMed
description
format Online
Article
Text
id pubmed-4042527
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40425272014-06-17 PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients Lu, P Hsu, J Keane, C Fettner, S Wang, J Ruperto, N Harari, O Brunner, HI De Benedetti, F Pediatr Rheumatol Online J Poster Presentation BioMed Central 2013-12-05 /pmc/articles/PMC4042527/ http://dx.doi.org/10.1186/1546-0096-11-S2-P171 Text en Copyright © 2013 Lu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Poster Presentation
Lu, P
Hsu, J
Keane, C
Fettner, S
Wang, J
Ruperto, N
Harari, O
Brunner, HI
De Benedetti, F
PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
title PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
title_full PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
title_fullStr PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
title_full_unstemmed PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
title_short PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
title_sort pres-final-2159: tocilizumab (tcz) dosing in juvenile idiopathic arthritis (jia): optimising for different jia type and body weight patients
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042527/
http://dx.doi.org/10.1186/1546-0096-11-S2-P171
work_keys_str_mv AT lup presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT hsuj presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT keanec presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT fettners presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT wangj presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT ruperton presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT harario presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT brunnerhi presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients
AT debenedettif presfinal2159tocilizumabtczdosinginjuvenileidiopathicarthritisjiaoptimisingfordifferentjiatypeandbodyweightpatients

Ejemplares similares